FDA seeks more information on Schering-Plough's Saphris

01/14/2009 | Star-Ledger (Newark, N.J.), The · Forbes

U.S. regulators requested more data from studies of Saphris, Schering-Plough's drug candidate for schizophrenia and bipolar disorder in adults. The FDA also made labeling recommendations but did not require additional trials. Schering said it will respond to the agency's concerns at the end of March.

View Full Article in:

Star-Ledger (Newark, N.J.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT